EUVIMEDEUVIMED entdecken
Crossref

Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward

Carlos Henrique Barrios, Tomás Reinert

AME Clinical Trials Review · 2026-04 · 4 · 19-19

DOI: 10.21037/actr-25-98 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Carlos Henrique Barrios und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Barrios, C. H., & Reinert, T. (2026). Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward. AME Clinical Trials Review, 4, 19-19. https://doi.org/10.21037/actr-25-98

Vancouver

Barrios CH, Reinert T. Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward. AME Clinical Trials Review. 2026;4:19-19. doi:10.21037/actr-25-98

BibTeX
@article{Barrios2026,
  author = {Barrios, Carlos Henrique and Reinert, Tomás},
  title = {Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward},
  journal = {AME Clinical Trials Review},
  year = {2026},
  volume = {4},
  pages = {19--19},
  doi = {10.21037/actr-25-98}
}
Kostenlos starten →